WallStreetZenWallStreetZen

NASDAQ: GLUE
Monte Rosa Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GLUE

Based on 6 analysts offering 12 month price targets for Monte Rosa Therapeutics Inc

Min Forecast
$19.00+74.79%
Avg Forecast
$25.50+134.59%
Max Forecast
$28.00+157.59%

Should I buy or sell GLUE stock?

Based on 6 analysts offering ratings for Monte Rosa Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although GLUE's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates GLUE as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their GLUE stock forecasts and price targets.

GLUE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-12
lockedlocked$00.00+00.00%2026-10-05
lockedlocked$00.00+00.00%2026-09-09
lockedlocked$00.00+00.00%2026-08-25
lockedlocked$00.00+00.00%2026-08-07
Wells Fargo
Top 2%
99
Strong BuyMaintains$27.00+148.39%2026-08-07

1 of 1

Forecast return on equity

Is GLUE forecast to generate an efficient return?

Company
-39.22%
Industry
21.05%
Market
175.22%
GLUE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GLUE forecast to generate an efficient return on assets?

Company
-27.65%
Industry
22.87%
GLUE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GLUE earnings per share forecast

What is GLUE's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$1.63
Avg 2 year Forecast
-$2.17
Avg 3 year Forecast
-$2.06

GLUE revenue forecast

What is GLUE's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$54.5M+89.64%
Avg 2 year Forecast
$37.6M+31.02%
Avg 3 year Forecast
$54.1M+88.19%
GLUE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GLUE revenue growth forecast

How is GLUE forecast to perform vs Biotechnology companies and vs the US market?

Company
18.27%
Industry
31.15%
Market
12.98%
GLUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GLUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GLUE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLUE$10.87$25.50+134.59%Strong Buy
ORIC$8.99$21.86+143.13%Strong Buy
MGTX$9.71$21.00+116.38%Buy
ANRO$23.47$39.75+69.37%Buy
SLN$19.80$26.00+31.31%Buy
View Top Biotech Stocks

Monte Rosa Therapeutics Stock Forecast FAQ

Is Monte Rosa Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: GLUE) stock is to Strong Buy GLUE stock.

Out of 6 analysts, 4 (66.67%) are recommending GLUE as a Strong Buy, 2 (33.33%) are recommending GLUE as a Buy, 0 (0%) are recommending GLUE as a Hold, 0 (0%) are recommending GLUE as a Sell, and 0 (0%) are recommending GLUE as a Strong Sell.

If you're new to stock investing, here's how to buy Monte Rosa Therapeutics stock.

What is GLUE's earnings growth forecast for 2026-2028?

(NASDAQ: GLUE) Monte Rosa Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.56%.

Monte Rosa Therapeutics's earnings in 2026 is -$161,116,000.On average, 11 Wall Street analysts forecast GLUE's earnings for 2026 to be -$138,685,465, with the lowest GLUE earnings forecast at -$168,886,409, and the highest GLUE earnings forecast at -$95,849,606. On average, 11 Wall Street analysts forecast GLUE's earnings for 2027 to be -$185,138,612, with the lowest GLUE earnings forecast at -$263,362,469, and the highest GLUE earnings forecast at -$93,162,234.

In 2028, GLUE is forecast to generate -$175,344,633 in earnings, with the lowest earnings forecast at -$250,821,399 and the highest earnings forecast at -$59,122,187.

What is GLUE's revenue growth forecast for 2026-2028?

(NASDAQ: GLUE) Monte Rosa Therapeutics's forecast annual revenue growth rate of 18.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.98%.

Monte Rosa Therapeutics's revenue in 2026 is $28,727,000.On average, 11 Wall Street analysts forecast GLUE's revenue for 2026 to be $4,647,703,460, with the lowest GLUE revenue forecast at $1,103,614,155, and the highest GLUE revenue forecast at $8,796,664,777. On average, 11 Wall Street analysts forecast GLUE's revenue for 2027 to be $3,211,025,787, with the lowest GLUE revenue forecast at $0, and the highest GLUE revenue forecast at $13,436,860,658.

In 2028, GLUE is forecast to generate $4,612,042,458 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $13,436,860,658.

What is GLUE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GLUE) forecast ROA is -27.65%, which is lower than the forecast US Biotechnology industry average of 22.87%.

What is GLUE's Price Target?

According to 6 Wall Street analysts that have issued a 1 year GLUE price target, the average GLUE price target is $25.50, with the highest GLUE stock price forecast at $28.00 and the lowest GLUE stock price forecast at $19.00.

On average, Wall Street analysts predict that Monte Rosa Therapeutics's share price could reach $25.50 by Oct 12, 2027. The average Monte Rosa Therapeutics stock price prediction forecasts a potential upside of 134.59% from the current GLUE share price of $10.87.

What is GLUE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GLUE) Monte Rosa Therapeutics's current Earnings Per Share (EPS) is -$1.76. On average, analysts forecast that GLUE's EPS will be -$1.63 for 2026, with the lowest EPS forecast at -$1.98, and the highest EPS forecast at -$1.12. On average, analysts forecast that GLUE's EPS will be -$2.17 for 2027, with the lowest EPS forecast at -$3.09, and the highest EPS forecast at -$1.09. In 2028, GLUE's EPS is forecast to hit -$2.06 (min: -$2.94, max: -$0.69).

What is GLUE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GLUE) forecast ROE is -39.22%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.